Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUASAR: Aflibercept 8 mg vs 2 mg in Macular Edema Secondary to Retinal Vein Occlusion
jRCT2031230147Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in Vein occlusion (RVO), branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO) and 1 more (3 arms), sponsored by Bayer. Primary endpoint: Change from baseline in BCVA (ETDRS letter score) at Week 36. Started Jan 2024; status: completed.
02
Drugs
aflibercept
03
Conditions
Vein occlusion (RVO)branch retinal vein occlusion (BRVO)central retinal vein occlusion (CRVO)hemiretinal vein occlusion (HRVO)
Beyond the preview
Go deeper on jRCT2031230147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230147.